George Goshua, EHA 2020: Endotheliopathy is Essential in COVID-19 Associated Coagulopathy
Access all of the content
Dr George Goshua (Yale University School of Medicine, New Haven, CT, USA) shares with us his insights into the role of endotheliopathy in the development of coagulopathy in patients with COVID-19.
Questions:
1. How common is coagulopathy in COVID-19 infection and who is at greatest risk? (0:03)
2. What is known about the role of endotheliopathy in the development of coagulopathy in patients with COVID-19? (1:39)
3. What is the link between the inflammatory response to SARS-CoV-2 and endotheliopathy? (2:23)
4. What practical advice would you give to physicians managing coagulopathy in patients with COVID-19 in terms of laboratory monitoring and anticoagulant therapy management? (3:33)
5. What can be done to identify high-risk populations? (5:33)
Abstract LB2605, Endotheliopathy is Essential in COVID-19 Associated Coagulopathy, is available at EHA25 Virtual here.
Speaker disclosure: George Goshua has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the Virtual Edition of the 25th European Hematology Association Annual Congress (EHA25 Virtual), June 2020.
COVID-19 = coronavirus disease 2019; SARS CoV-2 = severe acute respiratory syndrome coronavirus 2.
